

---

# Kluwer Patent Blog

## Patent case: Use of dexmedetomidine for sedation in intensive care units, Austria

Paul Reiter, Manuel Wegrostek (Gassauer-Fleissner Rechtsanwälte GmbH) · Monday, April 8th, 2019

The Higher Regional Court of Vienna confirmed that the “second medical use” of an already known substance, as required for patent protection, can be that the substance is used for a specific group of patients with specific effects.

Case date: 11 May 2017

Case number: 34R113/16m

Court: Higher Regional Court of Vienna

A full summary of this case has been published on [Kluwer IP Law](#).

---

*To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).*

## Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

---

79% of the lawyers think that the importance of legal technology will increase for next year.

**Drive change with Kluwer IP Law.**

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT  
The Wolters Kluwer Future Ready Lawyer  
Leading change



This entry was posted on Monday, April 8th, 2019 at 3:19 pm and is filed under [Austria](#), [Case Law](#), [Second Medical Use](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.